PSA testing is clinically accepted by the NACB and EGTM for both detection and monitoring1, 2.
- Quantitatively measures prostate-specific antigen in serum.
- Classic method to aid in the detection of prostate cancer.
- Used in conjunction with a digital rectal examination (DRE).
3rd Generation PSA Test2
Our 3rd Generation PSA assay aids in the detection of prostate cancer and is used as an adjunctive test to aid in the management of prostate cancer patients.
- Provides information on possible relapse in facilitating patient management.
- Provides an early indication of disease status after treatment when used in conjunction with other clinical information3.
- Approved for prostate cancer screening in conjunction with a digital rectal examination (DRE).
Free PSA Test
Our fPSA assay helps to guide decision-making in men 50 years or older who have DRE findings not suspicious of cancer who are in the diagnostics gray zone (4.0–10 ng/mL).
- Percent free PSA assessment may help to reduce unnecessary biopsies.4,5
- It helps to differentiate cancer from benign prostatic hyperplasia
- Percent free PSA is lower in prostate cancer than in benign prostate hyperplasia.4,5
Complexed PSA Test
The Siemens proprietary Complexed PSA is an alternative to traditional PSA testing for frontline detection.
- PSA complexed with ACT comprises a higher proportion of PSA in men with prostate cancer.6-8
- It is recommended as a frontline detection test.
- It is used in conjunction with a digital rectal examination (DRE).
1. NACB Laboratory Medicine Practice Guidelines. Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast and Ovarian Cancers. 2009.
2. The IMMULITE Third Generation PSA assay has not been evaluated and approved by the FDA for us with the IMMULITE Free PSA assay in the precent free PSA calculations.
3. Shen, et al. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy. J of Urol 2005; 173; 777-780.
4. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, Southwick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998 May 20;279(19):1542-7.
5. Lilja, et al. Significance of different molecular forms of serum PSA. Urol C Clin North Am 1993; 20:681:686.
6. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schwartz MK, Bruzek D J,Morris DL, Sokoll LJ, Chan DW, Yeung KK, Partin AW, Allard WJ. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol. 2000 Nov;164(5):1671-2.
7. Lilja H, Christtensson A, Matikainen M-T, et al. Prostate-specific antigen occurs predominantly in complex alpha-1-antichymotrypsin. Clin Chem 1991; 7:1618-25.
8. Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha-1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6.